# Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response

> **NCT06116461** · PHASE4 · UNKNOWN · sponsor: **Erasmus Medical Center** · enrollment: 34 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT06116461
- **Lead sponsor:** Erasmus Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-05
- **Primary completion:** 2024-10-01
- **Final completion:** 2025-01
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2024-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06116461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06116461, "Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06116461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*